On October 23, 2018, Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” ) closed an underwritten public offering of Class A Shares (“Common Shares”) of the Company at a price of $1.28 per Common Share for aggregate gross proceeds to the Company of $27,600,000 pursuant to an underwriting agreement dated October 4, 2018 with Mackie Research Capital Corporation (the “Underwriter”), as sole bookrunner and Underwriter.
Fasken advised Mackie Research Capital with a team led by Richard Steinberg and Jessica Catton Rinaldi and including Florind Polo, Laura Konkel (Securities/Corporate), Armand Benitah, Roxana Monemdjou (Intellectual Property), Timothy Squire, Mark Vanderveken (Regulatory), Mitchell Thaw (Tax), Jordana Keslassy and Gurinder Gujral (Articling Student).
Fasken advised Mackie Research Capital with a team led by Richard Steinberg and Jessica Catton Rinaldi and including Florind Polo, Laura Konkel (Securities/Corporate), Armand Benitah, Roxana Monemdjou (Intellectual Property), Timothy Squire, Mark Vanderveken (Regulatory), Mitchell Thaw (Tax), Jordana Keslassy and Gurinder Gujral (Articling Student).
